Melanoma News and Research

Latest Melanoma News and Research

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Researchers from Boston University School of Medicine (BUSM) have found that when attempting to pass tanning bed legislation, successful advocates collaborate with local and national organizations and lobbyists and have direct contact with the sponsoring legislator to aid in the passage of the bill. These findings, which appear on-line in the Journal of the American Academy of Dermatology, also identify strong lobbying efforts by the tanning bed industry as the biggest barrier to passing tanning bed legislation.

27 Mar 2010

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

American Academy of Dermatology Association (AADA) President and dermatologist William D. James, MD, FAAD, along with other dermatologists and leading researchers today testified before a Food and Drug Administration (FDA) panel considering changes to the current classification of indoor tanning devices. Currently, the FDA classifies indoor tanning devices as Class 1, the category for items that have minimal potential to cause harm to individuals. Items in Class 1 include adhesive bandages and tongue depressors.

27 Mar 2010

Two separate articles describing preclinical data of ACE-041 published

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.

26 Mar 2010

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.

24 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Sunbeds Bill to prevent under-18s from using tanning salons receives high-profile support

A Bill to prevent under-18s from using tanning salons has cleared its stages in the House of Commons, and will now go for consideration in the House of Lords.

17 Mar 2010

Research suggests anti-cancer drugs can help treat infectious diseases

Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.

16 Mar 2010

Study offers new possibilities for breast and other cancer therapies

Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.

16 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

Reducing collateral damage to excised tissue: Surgeons study device using radiofrequency energy

Every year more than 100,000 women in the United States undergo a lumpectomy, a conservative procedure to remove cancerous tumors while preserving the breast. The surgeon's goal is to attain a tumor-free, or negative, surgical margin the first time they operate. Current surgical tools may cause heat damage to the tissue samples needed for examination by a pathologist in order to identify the presence of cancerous cells on the edges of tumors.

15 Mar 2010

Prioritizing end of life care for cancer patients

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions.

15 Mar 2010

Provectus Pharmaceuticals receives $7.5M in private placement offering

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.

12 Mar 2010

New Maryland legislation protects minors from cancer risks caused by UV-radiation of indoor tanning

New Maryland legislation to protect youth from melanoma, the deadliest form of skin cancer, is based on significant scientific evidence that indoor tanning before the age of 30 is undeniably linked to increased risk of developing the disease. Senator James N. Robey and Delegate William A. Bronrott represent a broad-based coalition of 20 legislators in the Senate and House co-sponsoring cross-filed bills SB 718 and HB 1039 to prohibit minors' use of tanning devices in tanning facilities and prevent any marketing offers of these services to minors.

11 Mar 2010

Clinical and scientific advances made in the field of neuro-oncology

Many important clinical and basic scientific advances have been made in the past five years in the field of neuro-oncology, according to an editorial and several articles in the March issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

Genta announces private placement of Convertible Notes for $25M

Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.

8 Mar 2010

Melanoma News and Research

Latest Melanoma News and Research

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

Two separate articles describing preclinical data of ACE-041 published

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Nanotechnology weapons for cancer

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Sunbeds Bill to prevent under-18s from using tanning salons receives high-profile support

Research suggests anti-cancer drugs can help treat infectious diseases

Study offers new possibilities for breast and other cancer therapies

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Reducing collateral damage to excised tissue: Surgeons study device using radiofrequency energy

Prioritizing end of life care for cancer patients

Provectus Pharmaceuticals receives $7.5M in private placement offering

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

New Maryland legislation protects minors from cancer risks caused by UV-radiation of indoor tanning

Clinical and scientific advances made in the field of neuro-oncology

Genta announces private placement of Convertible Notes for $25M

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Melanoma News and Research

Latest Melanoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in